RE:It's a bell-curve thing.Just to clarify what you said about TLD-1433 becoming standard of care "with astounding swiftness". My understanding, and I may be wrong, is for TLT's bladder cancer therapy to become standard of care, we would have to succeed in a costly Ph3 trial in a head-to-head contest with BCG. Many here have suggested that in order to progress to Ph3 we will need a deep-pock pharma partner.
I'm not suggesting TLD-1433 won't eventually become standard, but it will take many years from where we are today. Hence it will not happen "with astounding swiftness". gojotv! wrote: Theshare price is in a doldrums, and it's a bell-curve thing.
You have some investors who completely get it, and are ravenous for shares, some who don't understand or believe in the tech at all and the majority in the middle...
They want to believe, but don't really "get" the science and doubt that this non-toxic, day-patient, highly effective treatment approach could possibly be true.
It's just too good.
And when you see reports day after day about people rejecting science, you realize why their dollars aren't flowing into TLT stock. But when this becomes THE new standard of care for bladder cancer (and when that happens, it will happen with astounding swiftness) the skepticism will subside and all eyes will be on TLT.
Just visualizing that makes the wait worthwhile.
And no idiotic talk about buyouts, please. What kind of fool sells his gold for a few copper pennies?
The Covid crisis made it clear that Canada needs its own Pharma-tech corporation to put us ahead of this and other crises in the future.
And I, for one, will be happy to collect dividends from my shares well into my old age.
Anyone who doesn't like that idea can sell now, please.